Skip to main content

Table 2 Demographic, clinical, and immunological data in association with the resistance mutations in the PR gene of the HIV-1 isolates

From: Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus – 1 (HIV-1) infected pediatric patients: a cross-sectional study

Parameters

PI associated resistance mutations

 

PI (+)

N = 13

PI (-)

N = 28

Age of study entry (Mean+/-SD, years)

10.2+/-5.2

10.6+/-2.7

Length of treatment (Mean+/-SD, years)

6.9+/-3.4

6.2+/-2.7

NNRTI therapy

9 (69.2%)

12 (42.9%)

TAMs mutations

10 (76.9%)

18 (64.3%)

3TC mutations

9 (64.2%) *

9 (32.1%)

NNRTI mutations

6 (46.1%)

12 (42.9%)

PI (secondary)

10 (76.9%) ***

15 (53.5%)

Clinical categories #

  

B

6 (46.1)

12/27 (44.4%)

C

7 (53.9%)

15/27 (55.6%)

Immune categories ##

  

1 (no suppression)

8 (61.5%)

16 (57.1%)

2–3 (moderate/severe)

5 (28.5%)

12 (42.9%)

PVL (n, %)

  

<10,000

1 (7.7%) **

14 (50.0%)

≥ 10,000

12 (92.3%)

14 (50.0%)

  1. Chi-square: * P < 0.02 ** P < 0.008 ***P < 0.0001
  2. # Immune categories based on age-specific CD4+ T-lymphocyte count.22,23
  3. ## B-moderately, C-severely symptomatic 22,23